Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Myositis Clinical Trials

A listing of Myositis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (15) clinical trials

Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD

Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many other connective tissue diseases (CTDs) such as polymyositis/dermatomyositis and mixed connective tissue disease. When ILD is ...

Phase

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

This is a proof of concept study to evaluate the efficacy, safety and tolerability of ABT in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.

Phase

Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis

Patients randomized to the HIIT protocol will train three days a week for 12 weeks. Before exercise start participants will rate self-reported pain and fatigue on a visual analogue scale and describe in own words information about possible changes in medication dose, any side effects from medication as well as ...

Phase N/A

Exercise in Sjogren Myositis and Takayasu's Arteritis

Exercise may improve physical capacity and health parameters in Primary Syndromes Sjogren, Myositis and Takayasu's Arteritis. Therefore, this study aims to investigate the role of an exercise training program in patients with Primary Syndromes Sjogren, Myositis and Takayasu's Arteritis.

Phase N/A

Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

Although there are several studies supporting the efficacy of tocilizumab (TCZ) in Rheumatoid Arthritis (RA) and systemic onset juvenile idiopathic arthritis, it's use in other autoimmune disorders has also been propose. A consensus statement on blocking the effects of IL-6 in RA and other autoimmune conditions has been recently published. ...

Phase

Belimumab in Idiopathic Inflammatory Myositis

Adults with refractory IIM will be enrolled. IIM is defined as Dermatomyositis (DM) or Polymyositis (PM), meeting the Bohan & Peter (1975) diagnostic criteria for definite or probable DM or PM. Refractory IIM is defined as chronic active IIM with a history of inadequate response or intolerance to three months ...

Phase

Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis

Calcinosis, a serious complication of dermatomyositis, involves deposition of calcium (carbonate apatite) in soft tissue, and can result in negative impacts on quality of life and physical function. To date, there are no known effective therapies that are approved for the treatment of dermatomyositis-associated calcinosis, and there is no consensus ...

Phase

Physical Training in Patients With Idiopathic Inflammatory Myopathies

To assess the impact of 12-weeks of physical training in patients with idiopathic inflammatory myopathies.

Phase N/A

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Phase

Study of Pioglitazone in Sporadic Inclusion Body Myositis

This is a 52-week, Phase 1, open-label, single center, proof of concept study of FDA-approved pioglitazone in adult patients with sporadic inclusion body myositis (sIBM). The trial consists of a 4-week screening period;16-week "lead-in" period during which all subjects are observed off-treatment. At Week 16, all subjects will be started ...

Phase